Novel lignan and stilbenoid mixture shows anticarcinogenic efficacy in preclinical PC-3M-luc2 prostate cancer model

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Yatkin, Emrah ^a   Polari, Lauri ^a   Laajala, Teemu D ^a   Smeds, Annika ^b   Eckerman, Christer ^b   Holmbom, Bjarne ^b   Saarinen, Niina M ^a   Aittokallio, Tero ^a,c   Mäkelä, Sari I ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ABIETIC ACID; ANTINEOPLASTIC AGENT; LIGNAN; MATAIRESINOL; METHYLPINOSYLVIN; NORTRACHELOGENIN; PINE KNOT EXTRACT; PINOSYLVIN; PLANT EXTRACT; RESVERATROL; STILBENOID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; FURAN DERIVATIVE; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ISOLATION; DRUG MEGADOSE; DRUG MIXTURE; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PHYTOCHEMISTRY; PROSTATE CANCER; SCOTS PINE; TUMOR VASCULARIZATION; ANIMAL; DRUG EFFECTS; PROSTATIC NEOPLASMS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FURANS; HETEROGRAFTS; HUMANS; LIGNANS; MALE; MICE; PINUS SYLVESTRIS; PLANT EXTRACTS; PROSTATIC NEOPLASMS; STILBENES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84899410874     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093764     Document Type: Article

References (45)

1. Lieberman R, Bermejo C, Akaza H, Greenwald P, Fair W, et al. (2001) Progress in prostate cancer chemoprevention: modulators of promotion and progression. Urology 58: 835-842. (Pubitemid 34017253)
2. Trottier G, Boström PJ, Lawrentschuk N, Fleshner NE (2010) Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol 7: 21-30.
3. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780.
4. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506. (Pubitemid 44136961)
5. Holmbom B, Eckerman C, Eklund P, Hemming J, Nisula L, et al. (2003) Knots in trees - A new rich source of lignans. Phytochem Rev 2: 331-340. (Pubitemid 41175234)
6. Willför S, Hemming J, Reunanen M, Holmbom B (2003) Phenolic and lipophilic extractives in Scots pine knots and stemwood. Holzforschung 57: 359-372.
7. Adlercreutz H (2007) Lignans and human health. Crit Rev Clin Lab Sci 44: 483-525.
8. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, et al. (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PloS One 6: e19881.
9. Landström M, Zhang JX, Hallmans G, Åman P, Bergh A, et al. (1998) Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 36: 151-161. (Pubitemid 28341126)
10. Bylund A, Zhang JX, Bergh A, Damber JE, Widmark A, et al. (2000) Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate 42: 304-314. (Pubitemid 30104574)
11. Lin X, Gingrich JR, Bao W, Li J, Haroon ZA, et al. (2002) Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urology 60: 919-924. (Pubitemid 35300377)
12. Bylund A, Saarinen N, Zhang JX, Bergh A, Widmark A, et al. (2005) Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo. Exp Biol Med 230: 217-223. (Pubitemid 40293695)
13. Li G, Rivas P, Bedolla R, Thapa D, Reddick RL, et al. (2012) Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev Res 6: 27-39.
14. Horvath Z, Marihart-Fazekas S, Saiko P, Grusch M, Ozsüy M, et al. (2007) Novel resveratrol derivatives induce apoptosis and cause cell cycle arrest in prostate cancer cell lines. Anticancer Res 27: 3459-3464. (Pubitemid 47607576)
15. Wang TT, Schoene NW, Kim YS, Mizuno CS, Rimando AM (2010) Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells. Mol Nutr Food Res 54: 335-344.
16. Lin X, Switzer BR, Demark-Wahnefried W (2001) Effect of mammalian lignans on the growth of prostate cancer cell lines. Anticancer Res 21: 3995-3999. (Pubitemid 34229275)
17. Karna P, Gundala SR, Gupta MV, Shamsi SA, Pace RD (2011) Polyphenol-rich sweet potato greens extract inhibits proliferation and induces apoptosis in prostate cancer cells in vitro and in vivo. Carsinogenesis 32: 1872-1880.
18. Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK (2010) Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One 5: e15627.
19. Kwon GT, Jung JI, Song HR, Woo EY, Jun JG, et al. (2012) Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling. J Nutr Biochem 23: 228-238.
20. Fulda S, Debatin K (2004) Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64: 337-346. (Pubitemid 38114116)
21. Peuhu E, Rivero-Müller A, Stykki H, Torvaldson E, Holmbom T, et al. (2010) Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis. Oncogene 29: 898-908.
22. Peuhu E, Paul P, Remes M, Holmbom T, Eklund P, et al. (2013) The antitumor lignan Nortrachelogenin sensitizes prostate cancer cells to TRAIL-induced cell death by inhibition of the AKT pathway and growth factor signaling. Biochem Pharmacol 86: 571-583.
23. Gonzalvez F, Ashkenazi A (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29: 4752-4765.
24. Smeds AI, Eklund P, Monogioudi E, Willför SM (2012) Chemical characterization of polymerized products formed in the reactions of matairesinol and pinoresinol with the stable radical 2,2-diphenyl-1-picrylhydrazyl. Holzforschung 66: 283-294.
25. Smeds AI, Hakala K, Hurmerinta TT, Kortela L, Saarinen N, et al. (2006) Determination of plant and enterolignans in human serum by high-performance liquid chromatography with tandem mass spectrometric detection. J Pharm Biomed Anal 41: 898-905. (Pubitemid 44269075)
26. Smeds AI, Eklund PC, Sjöholm RE, Willför SM, Nishibe S, et al. (2007) Quantification of a broad spectrum of lignans in cereals, oilseeds, and nuts. J Agric Food Chem 55: 1337-1346.
27. Smeds AI, Saarinen NM, Eklund PC, Sjöholm RE, Mäkelä SI (2005) New lignan metabolites in rat urine. J Chromatogr B Analyt Technol Biomed Life Sci 816: 87-97. (Pubitemid 40143494)
28. Mahalanobis PC (1936) On the generalised distance in statistics. Proc Nat Instit Sci India 12: 49-55.
29. De Maesschalck R, Jouan-Rimbaud D, Massart DL (2000) The Mahalanobis distance. Chemometr Intell Lab 50: 1-18. (Pubitemid 30019315)
30. Hutz JE, Nelson T, Wu H, McAllister G, Moutsatsos I, et al. (2013) The multidimensional perturbation value: a single metric to measure similarity and activity of treatments in high-throughput multidimensional screens. J Biomol Screen 18: 367-377.
31. Venkateswaran V, Klotz LH (2010) Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol 7: 442-453.
32. Park EJ, Chung HJ, Park HJ, Kim GD, Ahn YH, et al. (2013) Suppression of Src/ERK and GSK-3/β-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells. Food Chem Toxicol 55: 424-433.
33. Laajala TD, Corander J, Saarinen NM, Mäkelä K, Savolainen S, et al. (2012) Improved statistical modeling of tumor growth and treatment effect in preclinical animal studies with highly heterogeneous responses in vivo. Clin Cancer Res 18: 4385-4396.
34. Scalbert A, Williamson G (2000) Dietary Intake and Bioavailability of Polyphenols. J Nutr 130: 2073S-2085S. (Pubitemid 30619386)
35. Wiezorek J, Holland P, Graves J (2010) Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 16: 1701-1708.
36. Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA, et al. (2005) Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J Exp Ther Oncol 5: 81-91. (Pubitemid 41739368)
37. Shankar S, Siddiqui I, Srivastava R (2007) Molecular mechanism of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem 304: 273-285. (Pubitemid 47456876)
38. Szliszka E, Helewski KJ, Mizgala E, Krol W (2011) The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells. Int J Oncol 39: 771-779.
39. Roupe K, Halls S, Davies NM (2005) Determination and assay validation of pinosylvin in rat serum: application to drug metabolism and pharmacokinetics. J Pharm Biomed Anal 38: 148-154. (Pubitemid 40725101)
40. Smeds AI, Saarinen NM, Hurmerinta TT, Penttinen PE, Sjöholm RE, et al. (2004) Urinary excretion of lignans after administration of isolated plant lignans to rats: the effect of single dose and ten-day exposures. J Chromatogr B Analyt Technol Biomed Life Sci 813: 303-312. (Pubitemid 39535459)
41. McCann MJ, Gil IRC, Linton T, Berrar D, McGlynn H, et al. (2008) Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro. Mol Nut Food Res 52: 567-580.
42. Wang TTY, Hudson TS, Wang TC, Remsberg CM, Davies NM, et al. (2008) Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carsinogenesis 29: 2001-2010.
43. Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, et al. (2007) Resveratrol suppresses prostate cancer progression in transgenic mice. Carsinogenesis 28: 1946-1953. (Pubitemid 47500607)
44. Xu Q, Si LY (2012) Resveratrol role in cardiovascular and metabolic health and potential mechanisms of action. Nutr Res 32: 648-658.
45. Scott E, Steward WP, Gescher AJ, Brown K (2012) Resveratrol in human cancer chemoprevention-choosing the 'right' dose. Mol Nutr Food Res 56: 7-13.